Cybersecurity requirements, which are being debated in Brussels these months, could herald markedly higher encryption and cybersecurity expenses for many firms, including those in the life sciences industry, as evident in the European Commission's impact assessment of its revised cybersecurity directive proposal, the NIS2.
Were it only up to the Commission and members of the European Parliament, more companies – including, for instance, drugmakers – would face new rules pertaining to encryption and the reporting of cyberattacks, and more.
Already a subscriber? Log in.
Read the whole article
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.Start a free company trial today
Your trial for MedWatch has now started
With your free trial you get:
Full access to all locked articles on MedWatch.
Daily newsletter and ongoing top-newsletters. You can unsubscribe and subscribe to our newsletters anytime.
When your trial period expires
You will not be transferred to a paid subscription.
You will continue to receive our newsletters after the trial period expires. You can unsubscribe at the bottom of each newsletter.